Earn CME: https://naccme.com/program/7311
In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Koen van Besien discusses whether acute myeloid leuekemia patients between the ages of 60 and 80 should receive an allogeneic stem cell transplant.
© 2018 Imedex, an HMP Company